

[< Back](#)

Advertise

ChemistrySelect / Volume 5, Issue 19 / p. 5756-5762

Full Paper

Auto QSAR- A Fast Approach for Creation and Application of QSAR Models through Automation

Kshipra S. Karnik, Ishudeep Singh Narula, Dr. Aniket P. Sarkate, Dr. Pravin S. Wakte 


First published: 20 May 2020

<https://doi.org/10.1002/slct.202000744>

Citations: 3

Graphical Abstract

An Auto-QSAR methodology has been used in this work along with molecular docking strategy on phenoxyquinoline c-Met kinase inhibitors. QSAR models were re-validated and comparison of predicted activity with the literature observed activity showed that compound **18 b** as most potent c-Met kinase inhibitor. Moreover, obtained compounds were subjected to *in silico* ADMET studies to screen the drug-likeness and toxicity properties.

[Back](#)

Abstract

A continuous and undefined malignant growth in cancer makes it an extremely heterogeneous complex disease. Different types of enzymes helps in detection of cancerous growth in the human body. In this work, different predictive Quantitative Structure-Activity Relationship (QSAR) models by means of various molecular modeling techniques using 43 novel 6, 7-disubstituted-4-phenoxyquinoline derivatives acting as Tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR) (c-Met kinase) inhibitors were designed. Best QSAR models were generated through Auto QSAR. Predicted activity of these models was compared with the observed activity from literature, and it was observed that potent compound **18 b** gave high docking results. Auto-QSAR technique provided the perfect model for the designed derivatives. Binding affinity of compounds for c-Met kinase enzyme was studied by molecular docking and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA dG) binding studies. Optimized compounds were subjected to *in silico* ADMET studies for predicting drug-likeness and toxicity properties. Reported work will assist to design, refine and construct the novel phenoxyquinoline derivatives as potent c-Met kinase inhibitors in near future.

Conflict of interest

[Back](#)

Supporting Information

As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.

Filename	Description
slct202000744-sup-0001-misc_information.pdf 229.5 KB	Supplementary

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

References

1 E. S. Qamsari, S. S. Ghaderi, B. Zarei, R. Dorostkar, S. Bagheri, F. Jadidi-Niaragh, M. H. Somi, M. Yousefi, *Tum. Biol.* 2017, **39**, 1–13.

[Google Scholar](#)

2 S. Hammad, R. Meghnam, D. Meziane, S. Bouaziz-Terrachet, *Int. J. Drug Dev. & Res.* 2017, **9**, 33–40.

[CAS](#) | [Google Scholar](#)

3 Y. C. Lim, H. J. Kang, J. H. Moon, *Oral Oncol.* 2014, **50**, 633–639.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

4 L. Ruco S Scarpino, *Biomed.* 2014, **2**, 263–274.

[Google Scholar](#)

5 J. Bean, C. Brennan, J. Y. Shih, *Proc. Mont. Acad. Sci.* 2007, **104**, 20932–20937.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

[Back](#)[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

7 N. P. Gunasinghe, A. Wells, E. W. Thompson, *Can. Met. Rev.* 2012, **31**, 469–478.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

8 C. Tang, D. L. Jardim, G. S. Falchook, *Oncoscience* 2013, **1**, 5–13.

[PubMed](#) | [Google Scholar](#)

9 D. Delitto, G. E. Vertes, S. J. Hughes, *World J. Gastroenterol.* 2014, **20**, 8458–8470.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

10 P. A. Humphrey, X. Zhu, R. Zarnegar, *Am. J. Pathol.* 1995, **147**, 386–396.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

11 Y. Liu, X. F. Yu, J. Zou, *World J. Gastroenterol.* 2015, **21**, 3706–3710.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

12 P. Szturz, E. Raymond, C. Abitbol, S. Albert, A. de Gramont, S. Faivre, *Crit. Rev. Oncol. Hematol.* 2017, **111**, 39–51.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

13 B. Kim, N. Jung, S. Lee, J. K. Sohng, H. J. Jung, *Phytother. Res.* 2016, **30**, 1833–1840.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

14 S. Bender, J. Gronych, H. J. Warnatz, *Nat. Med.* 2016, **22**, 1314–1320.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

15 J. A. Engelman, K. Zejnullahu, T. Mitsudomi, *Science* 2007, **316**, 1039–1043.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

[< Back](#)[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

17 N. Sahrma, A. Adjei, *Ther. Adv. Med. Oncol.* 2011, **3**, 37–50.

[Google Scholar](#)

18 E. C. Smyth, F. Sciafani, D. Cunningham, *Oncol. Targets Ther.* 2014, **7**, 1001–1014.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

19 P. Blume-Jensen, T. Hunter, *Nature* 2001, **411**, 355–365.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

20 P. Longati, P. M. Comoglio, A. Bardelli, *Curr. Drug Targets* 2001, **2**, 41–55.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

21 G. Maulik, A. Shrikhande, T. Kijima, P. C. Ma, P. T. Morrison, R. Salgia, *Cyto. Gro. Fact. Rev.* 2002, **13**, 41- 59.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

22 C. L. Arteaga, F. Khuri, G. Krystal, S. Sebti, *Semin. Oncol.* 2002, **29**, 15–26.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

23 Q. Tang, Y. Zhao, X. Du, L. Chong, P. Gong, C. Guo, *Eur. J. Med. Chem.* 2013, **69**, 77–89.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

24 C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, *Adv. Drug Delivery Rev.* 2012, **64**, 4–17.

[Web of Science®](#) | [Google Scholar](#)

25 D. K. Lokwani, R. Azad, A. P. Sarkate, P. Reddanna, D. B. Shinde, *Bioorg. Med. Chem.* 2015, **23**, 4533–4543.

[< Back](#)

26 S. V. Tiwari, J. A. Saijas, M. P. Vazquez-Tato, A. P. Sarkate, K. S. Karnik, A. P. G. Nikalje, *Molecules* 2017, **22**, 1–18.

[Google Scholar](#)

27 S. V. Tiwari, J. A. Seijas, M. P. Vazquez-Tato, A. P. Sarkate, K. S. Karnik, A. P. G. Nikalje, *Molecules* 2018, **23**, 1–23.

[Web of Science®](#) | [Google Scholar](#)

28 M. R. Bhosle, L. D. Khillare, J. R. Mali, A. P. Sarkate, D. K. Lokwani, S. V. Tiwari, *New J. Chem.* 2018, **42**, 18621–18632.

[CAS](#) | [Web of Science®](#) | [Google Scholar](#)

29 T. R. Deshmukh, A. P. Sarkate, D. K. Lokwani, S. V. Tiwari, R. Azad, B. B. Shingate, *Bioorg. Med. Chem. Lett.* 2019, **29**, 1–8.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

Citing Literature



[Download PDF](#)

© 2024 Wiley-VCH GmbH, Weinheim

ABOUT WILEY ONLINE LIBRARY

[Privacy Policy](#)

[Terms of Use](#)

[About Cookies](#)

[Manage Cookies](#)

[Accessibility](#)

[Wiley Research DE&I Statement and Publishing Policies](#)

< Back

Training and Support
DMCA & Reporting Piracy

OPPORTUNITIES

Subscription Agents
Advertisers & Corporate Partners

CONNECT WITH WILEY

The Wiley Network
Wiley Press Room

Copyright © 1999-2024 John Wiley & Sons, Inc or related companies. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.